Invitation to Asarina Pharma R&D Day 2020
Asarina Pharma invites institutional investors, financial analysts and media to join its R&D day, focused on the upcoming Study results in the company's lead indication PMDD.
Date: March 26, 2020
Time: 14.00-17.00, registration from 13.30
Location: Helio GT30, Grev Turegatan 30, Stockholm
With presentations from PMDD practitioners and patients, as well as Asarina Pharma’s leading researchers and managers, the day will give a broad picture of PMDD, what the most meaningful clinical effects for a treatment are, and how the company's upcoming Phase IIb data will be evaluated and presented.
Doctor Paula Briggs: Lead study investigator, Liverpool Woman’s Hospital, consultant in sexual and reproductive health.
Professor Torbjörn Bäckström: Founder and CSO Asarina Pharma, Professor Dept. Clinical Sciences, Obstetrics and Gynecology Umeå University.
Karin Ekberg, PhD: Chief Operating Officer, Asarina Pharma.
Paula ‘Fenjima’ Manrique: PMDD patient and advocate, writer, speaker, regular guest as Gaming Expert on Swedish TV4:s Nyhetsmorgon.
Doctor Peter Nordkild: CEO Asarina Pharma.
The event will also offer some insights into Asarina Pharma's other ongoing research into menstrual migraine and Tourette syndrome.
Please register for R&D Day at the following link: https://financialhearings.com/event/12602/register/live_event
We look forward to meeting you!
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
About Asarina Pharma
We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.